An experimental treatment aimed at helping people with severe peanut allergy scored a clinical win Tuesday, putting it in line to possibly become the first drug to provide meaningful protection against accidental exposure.

Based on the positive results, Aimmune Therapeutics (AIMT) expects to seek U.S. approval for its preventative peanut allergy therapy by the end of the year, with a European filing in 2019, the company said.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a ~65-year-old with a life-long severe peanut allergy I find this article a little amusing but noted that it does conclude there is no cure for a peanut allergy so BRAVO.
    From my experience
    1. The only viable cure for ingesting peanut products is to expel them; and
    2. I have always coached others and suggested parents teach their children to
    a. quickly identify when they are having an allergic reaction; then
    b. immediately expel the peanuts from their system (aka vomit)
    3. The recovery time is basically 1:1 (i.e. 30 minutes ingested = 30 minutes to recover or stabilize)
    My sense is relying on immunotherapy or an EpiPen is not prudent and a bad strategy since it only masks the symptoms and fails to address the root cause which, unless it is expelled, must then pass through the sufferer’s system over the next 12-24 hours. Why would/should anyone subject themselves or others to that misery?

  • Fun fact:

    this “exceptional” compound, AR101, is nothing other than defatted powdered lightly roasted peanut flour! Used sprinkled on food about to be eaten to desensitize the subject (all above data from their efficacy and safety study). And the challenging amount in the trial was equivalent to three peanut kernels.
    Basically, the whole business is pointless as I don’t see how you can forbid any nut/food company out there to sell powdered defatted peanuts at 100 mg doses in the supermarket. Or even better, you can grind half a kernel of roasted peanuts yourself on your food, and you get the same (I believe the fat is not therapeutically particularly relevant).
    But, “sophisticated” investors and their “qualified” consultants surely know better.

    When I read this stories (like the Innate Immunotherapeutics one), I wonder if everyone from the visionary entrepreneurs, to the investors, consultants, FDA representatives and journalists are just a bunch of ignorant m***ns, or more or less skilled scammers.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy